DrugCite
Search

NOOTROPYL

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Nootropyl Adverse Events Reported to the FDA Over Time

How are Nootropyl adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Nootropyl, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Nootropyl is flagged as the suspect drug causing the adverse event.

Most Common Nootropyl Adverse Events Reported to the FDA

What are the most common Nootropyl adverse events reported to the FDA?

Aggression
8 (3.67%)
Hallucination, Visual
8 (3.67%)
Hypothyroidism
8 (3.67%)
Altered State Of Consciousness
6 (2.75%)
Extrapyramidal Disorder
6 (2.75%)
Hypoglycaemia
6 (2.75%)
Renal Failure Acute
6 (2.75%)
Disorientation
5 (2.29%)
Malaise
5 (2.29%)
Renal Failure
5 (2.29%)
Abnormal Behaviour
4 (1.83%)
Show More Show More
Anaemia
4 (1.83%)
Conjunctivitis
4 (1.83%)
Loss Of Consciousness
4 (1.83%)
Rash Erythematous
4 (1.83%)
Torsade De Pointes
4 (1.83%)
Aspiration
3 (1.38%)
Blood Creatinine Increased
3 (1.38%)
Cardiac Arrest
3 (1.38%)
Confusional State
3 (1.38%)
Dyspnoea
3 (1.38%)
Fluid Retention
3 (1.38%)
Hyperthermia
3 (1.38%)
Oedema
3 (1.38%)
Product Quality Issue
3 (1.38%)
Sinus Bradycardia
3 (1.38%)
Skin Exfoliation
3 (1.38%)
Subdural Haematoma
3 (1.38%)
Thrombocytopenia
3 (1.38%)
Ventricular Extrasystoles
3 (1.38%)
Ventricular Hypertrophy
3 (1.38%)
Bradycardia
2 (.92%)
Condition Aggravated
2 (.92%)
Cytolytic Hepatitis
2 (.92%)
Device Misuse
2 (.92%)
Dizziness
2 (.92%)
Drug Interaction
2 (.92%)
Dysarthria
2 (.92%)
Eosinophil Count Increased
2 (.92%)
Erythema
2 (.92%)
Headache
2 (.92%)
Hypokalaemia
2 (.92%)
Hypothermia
2 (.92%)
Impaired Gastric Emptying
2 (.92%)
Pyrexia
2 (.92%)
Somnolence
2 (.92%)
Syncope
2 (.92%)
Syringe Issue
2 (.92%)
White Blood Cell Count Increased
2 (.92%)
Agitation
1 (.46%)
Atrial Fibrillation
1 (.46%)
Blood Glucose Increased
1 (.46%)
Blood Pressure Decreased
1 (.46%)
Brain Herniation
1 (.46%)
Cerebellar Syndrome
1 (.46%)
Cerebral Atrophy
1 (.46%)
Cerebral Ventricle Dilatation
1 (.46%)
Cholestasis
1 (.46%)
Circulatory Collapse
1 (.46%)
Constipation
1 (.46%)
Creatinine Renal Clearance Decrease...
1 (.46%)
Cyclitis
1 (.46%)
Depression
1 (.46%)
Dermatitis Exfoliative
1 (.46%)
Device Malfunction
1 (.46%)
Device Occlusion
1 (.46%)
Duodenal Ulcer
1 (.46%)
Dyskinesia
1 (.46%)
Electrocardiogram Qt Prolonged
1 (.46%)
Eosinophilia
1 (.46%)
Eye Movement Disorder
1 (.46%)
Fall
1 (.46%)
Fatigue
1 (.46%)
General Physical Health Deteriorati...
1 (.46%)
Generalised Erythema
1 (.46%)
Hepatitis
1 (.46%)
Hypertonia
1 (.46%)
Hyphaema
1 (.46%)
Hypotension
1 (.46%)
Idiopathic Thrombocytopenic Purpura
1 (.46%)
Incorrect Drug Administration Rate
1 (.46%)
International Normalised Ratio Incr...
1 (.46%)
Iridocyclitis
1 (.46%)
Leukocytosis
1 (.46%)
Monoparesis
1 (.46%)
Myoclonus
1 (.46%)
Neutropenia
1 (.46%)
Orthostatic Hypotension
1 (.46%)
Personality Change
1 (.46%)
Presyncope
1 (.46%)
Psychomotor Retardation
1 (.46%)
Renal Impairment
1 (.46%)
Retinal Detachment
1 (.46%)
Shock
1 (.46%)
Subarachnoid Haemorrhage
1 (.46%)
Subdural Haematoma Evacuation
1 (.46%)
Subileus
1 (.46%)
White Blood Cell Count Decreased
1 (.46%)
Wrong Technique In Drug Usage Proce...
1 (.46%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Nootropyl, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nootropyl is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Nootropyl

What are the most common Nootropyl adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Nootropyl, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nootropyl is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Nootropyl According to Those Reporting Adverse Events

Why are people taking Nootropyl, according to those reporting adverse events to the FDA?

Drug Use For Unknown Indication
16
Epilepsy
3
Vertigo
2
Unevaluable Event
2
Memory Impairment
1
Nervous System Disorder
1
Show More Show More
Depression
1
Ill-defined Disorder
1
Cerebrovascular Accident
1
Hypertension
1
Product Used For Unknown Indication
1

Nootropyl Case Reports

What Nootropyl safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Nootropyl. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Nootropyl.